On Tuesday, BioNTech SE (NASDAQ:BNTX) stock received an upgrade from a Jefferies analyst, who changed the rating from Hold to Buy and increased the price target to $150 from the previous $96. The upgrade was driven by the potential of BioNTech's investigational drug BNT327, which could significantly impact the company's revenue.
The analyst noted that despite molecular differences, BNT327 has shown similar efficacy to a competing drug in early data. The drug is a bispecific antibody targeting VEGF/PDL1, and there is a substantial opportunity for its use in combination therapies for non-small cell lung cancer (NSCLC) and other cancers. The firm's positive outlook is based on the drug's potential market in first-line (1L) and second-line (2L) NSCLC treatments, among others.
BioNTech's strong cash position is seen as an advantage that could allow the company to conduct parallel Phase 3 pivotal trials. The financial modeling by Jefferies includes a €3.6 billion risk-adjusted peak sales forecast for BNT327. The analyst expressed a heightened conviction in the drug's VEGF/PDL1 mechanism, which is expected to bolster BioNTech's antibody-drug conjugate (ADC) combination strategy.
The projected sales figures take into account a variety of possible treatment combinations and stages of cancer, assigning probabilities of success (PoS) to each. For 1L NSCLC, a 25% PoS was modeled, while 2L+ NSCLC, small cell lung cancer (SCLC) combinations, and triple-negative breast cancer (TNBC) combinations each have a 45% PoS. This comprehensive analysis underpins the firm's decision to raise the price target and upgrade the stock to Buy.
In other recent news, TD Cowen has maintained a Hold rating on BioNTech's shares, with emphasis on the potential of BNT327, an investigational drug targeting multiple tumor types. BNT327's impressive performance was underlined at the European Society for Medical Oncology meeting.
H.C. Wainwright reaffirmed its Buy rating for BioNTech, highlighting the clinical trial results for the investigational therapy, BNT211. JPMorgan upgraded BioNTech's stock from Underweight to Neutral, raising the price target from $91 to $125, based on promising data from the company's phase II and phase I/II trials for BNT327/PM8002.
BofA Securities increased its price target for BioNTech to $150 from $125, following updates from its oncology pipeline at the European Society for Medical Oncology conference. Jefferies also lifted its price target on BioNTech's shares, reflecting the potential of the investigational drug BNT327.
BioNTech has entered a multi-year collaboration with Tempus AI, Inc., aiming to enhance its oncology research and development. The company, in partnership with Pfizer (NYSE:PFE), received FDA approval for an updated COVID-19 vaccine designed for the Omicron KP.2 variant. Lastly, BioNTech and DualityBio were granted Fast Track designation by the FDA for their investigational drug, BNT324/DB-1311, for treating metastatic castration-resistant prostate cancer.
InvestingPro Insights
The recent upgrade by Jefferies reflects a growing confidence in BioNTech SE's (NASDAQ:BNTX) pipeline and its potential to drive future revenues. Supporting this outlook, InvestingPro Tips highlight that the company holds more cash than debt on its balance sheet, which could indeed facilitate the aggressive development of its investigational drug BNT327. Additionally, despite a challenging market, BioNTech has seen a significant return over the last week, which may reflect investor optimism following the upgrade.
Looking at the real-time data from InvestingPro, BioNTech's market capitalization stands at $29.36 billion. While the company's P/E ratio is negative at -53.61, indicating a lack of profitability in the last twelve months as of Q2 2024, the strong gross profit margin of 82.91% suggests that the underlying business remains robust. However, analysts have concerns about the short-term, with six analysts revising their earnings downwards for the upcoming period and anticipating a sales decline in the current year.
For readers interested in a deeper dive into BioNTech's financial health and future prospects, there are additional InvestingPro Tips available at https://www.investing.com/pro/BNTX, which provide further insights into the company's performance and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.